ArticleBulletin of the World Health Organization2026
Hepatitis A virus endemicity and vaccine policy, India.
Article in Bulletin of the World Health Organization, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To estimate the age-stratified, hepatitis A virus (HAV) seroprevalence in eight Indian states. Methods: A cross-sectional seroprevalence survey was conducted in 120 rural and 105 urban population clusters across eight Indian states between 12 December 2022 and 28 November 2023. In each cluster, ten participants were randomly selected from each of the age groups: (i) 2 to 4 years; (ii) 5 to 9 years; (iii) 10 to 14 years; (iv) 15 to 30 years; and (v) > 30 years. Serum samples were tested for anti-HAV antibodies. Findings: Overall, the HAV seroprevalence in the five age groups was 33.2% (95% confidence interval, CI: 30.4-36.2), 51.9% (95% CI: 49.0-54.8), 69.2% (95% CI: 66.6-71.8), 89.7% (95% CI: 88.6-90.8) and 97.4% (95% CI: 96.9-97.8), respectively. The female-to-male ratio was 1.52 : 1 and the HAV seroprevalence was 73.0% (4940/6768) in females versus 63.2% (2821/4453) in males. Overall, HAV endemicity was found to be high-intermediate in study groups in Gujarat, Jammu, Karnataka, Punjab and Rajasthan, high in Bihar, intermediate in Assam and low-intermediate in rural Manipur. As the overall seroprevalence for all children younger than 15 years was 51.9%, substantially more than 40% were at risk of HAV infection. Conclusion: Although HAV endemicity varied widely across urban and rural study populations in the eight Indian states, it was generally high-intermediate, providing evidence that HAV endemicity in India has declined in recent years. The study's findings could help Indian policy-makers decide on HAV vaccination for children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.